" class="no-js "lang="en-US"> Jacob Van Naarden - Medtech Alert
Saturday, March 25, 2023

Breaking News

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Celyad Oncology Appoints Georges Rawadi as Its New CEO Companion Spine Closes $60.1 Million Series A Funding Round EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases
Jacob Van Naarden

Jacob Van Naarden

About Jacob Van Naarden

Related Story

Appointments

 New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions | Pharmtech Focus

Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly

August 12 2022

Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, […]

Diseases

 Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform | Pharmtech Focus | Pharmtech Focus

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

December 13 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics […]

Appointments

 Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units | Pharmtech Focus

Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units

August 17 2021

Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience […]

Diseases

 Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses | Pharmtech Focus

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

July 29 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and […]